Pretax income is the income that a company earns before paying income taxes. Illumina's pretax income for the
three
months ended in Mar. 2022 was $140 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Mar. 2022 was $853 Mil.
Illumina's pretax margin was 11.45%.
During the past 13 years, Illumina's highest Pretax Margin was 37.90%. The lowest was 11.21%. And the median was 25.19%.
Illumina Pre-Tax Income Historical Data
The historical data trend for Illumina's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Illumina Annual Data
Trend
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Pre-Tax Income
1,043.00
894.00
1,118.00
856.00
884.00
Illumina Quarterly Data
Jun17
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Pre-Tax Income
169.00
207.00
420.00
86.00
140.00
Competitive Comparison
For the Diagnostics & Research subindustry, Illumina's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Illumina Pre-Tax Income Distribution
For the Medical Diagnostics & Research industry and Healthcare sector, Illumina's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Illumina's Pre-Tax Income falls into.
Illumina Pre-Tax Income Calculation
This is the income that a company earns before paying income taxes.
Illumina's Pretax Income for the fiscal year that ended in Dec. 2021 is calculated as
Pre-Tax Income for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $853 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Illumina (NAS:ILMN) Pre-Tax Income Explanation
Illumina's Pretax Margin for the quarter that ended in Mar. 2022 is calculated as
During the past 13 years, Illumina's highest Pretax Margin was 37.90%. The lowest was 11.21%. And the median was 25.19%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Illumina Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Illumina's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates revenue from sequencing tools and dedicated consumables (76% of 2020 sales). Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications. Services account for 16% of sales and include basic maintenance services, clinical lab applications (such as noninvasive prenatal, oncology, and rare-disease screening), and whole genome sequencing.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
1.14(0.47%) Volume: 347,264 1:24PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:ILMN has been successfully added to your 
